Related Jobs
-
Clinical Research Associate
Job Type: Permanent
Salary: Salary on application
Location: Croatia -
Rédacteur Scientifique (H/F)
Job Type: Contract
Salary: € 3200.00 per month
Location: France - Field Based
AstraZeneca drug shows promise in breast cancer
02 Jan 2007
Clinical Research
Clinical work on a new AstraZeneca drug has shown its potential to treat hormone-receptor positive (HR+) breast cancer, the company reports.
Faslodex (fulvestrant) was tested in women who have received a course of non-steroidal aromatase inhibitor (NSAI) therapy but whose cancer has progressed or recurred.
The 'Efect' trial compared Faslodex with exemestane (a Pfizer drug marketed as Aromasin), with the AstraZeneca drug showing slightly higher levels of progression-free survival and disease stabilisation.
"The primary goal of treatment for advanced breast cancer is to slow or halt the progression of the disease whilst maintaining a woman's quality of life. Until recently, treatment options for women progressing or recurring after NSAI therapy were restricted due to the lack of clinical data in this setting," said Dr Peter Barrett-Lee from Velindre Hospital, Cardiff.
"As more women continue to receive AIs earlier in the treatment sequence, Efect provides thefirst large-scale study to examine alternative endocrine options for this important patient population," he added.
Though the difference between the treatment populations was relatively small, the company claims this result does offer hope to those who are no longer benefiting from AI treatment.
AstraZeneca has had a tough year on development, with stroke drug NXY-059 failing clinical trials and heartburn treatment Nexium losing patent protection.
© Adfero Ltd
